(Total Views: 47)
Posted On: 07/29/2025 4:05:15 PM
Post# of 94
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company developing inflammation and immunology biological products and providing boutique CDMO services, announced the publication of a peer-reviewed article in the Journal of Dermatological Treatment confirming the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study demonstrated PC111’s ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, offering a differentiated, non-immunosuppressive approach. Data also highlighted potential use in SJS/TEN, a life-threatening dermatological condition. CEO Amir Reichman said the findings reinforce PC111’s potential to transform treatment for these high unmet-need indications and deliver meaningful value to patients and shareholders.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company developing inflammation and immunology biological products and providing boutique CDMO services, announced the publication of a peer-reviewed article in the Journal of Dermatological Treatment confirming the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study demonstrated PC111’s ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, offering a differentiated, non-immunosuppressive approach. Data also highlighted potential use in SJS/TEN, a life-threatening dermatological condition. CEO Amir Reichman said the findings reinforce PC111’s potential to transform treatment for these high unmet-need indications and deliver meaningful value to patients and shareholders.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
